Lisa Soyeon Park

Lisa Soyeon Park has held various roles throughout their career. Lisa Soyeon began their career at Biomedlab Co. in 1999, where they served as the Director of Biochip R&D until 2004. From 2004 to 2009, they worked at the Korea Institute of Toxicology as the Director of Business Development & Regulatory Affairs. In 2009, they joined Qion Pte Ltd as the CSO, a role they held until 2015. Since 2015, Lisa has been the CEO of Prestige BioPharma Ltd.

Lisa Soyeon Park completed their PhD in Bioorganic Chemistry/Analytical Chemistry at the University of Missouri-Columbia from 1991 to 1995. Lisa Soyeon then pursued a Postdoc degree in Toxicology/Environmental Health at the Massachusetts Institute of Technology from 1996 to 1999.